Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Cara Therapeutics (Nasdaq: CARA) announced that Christopher Posner, CEO, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 11:15 a.m. PST. The presentation will provide an overview of the company's innovative approach to treating pruritus. Cara's KORSUVA® (difelikefalin) injection is the first FDA-approved treatment for moderate-to-severe pruritus in chronic kidney disease patients on hemodialysis. A webcast will be available on the company's website and archived for 30 days.

Positive

• KORSUVA® is the first FDA-approved treatment for pruritus in chronic kidney disease patients.
• Company developing oral formulation of difelikefalin, expanding treatment options.
• Phase 3 programs initiated for pruritus in advanced chronic kidney disease and atopic dermatitis.

Negative

• None.

STAMFORD, Conn., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present a company overview at the 41^st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 11:15 a.m. PST (2:15 p.m. EST) in San Francisco, CA.

A webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com

 

FAQ

When is Cara Therapeutics presenting at the J.P. Morgan Healthcare Conference?

Cara Therapeutics will present on January 9, 2023, at 11:15 a.m. PST.

What is KORSUVA® and its significance?

KORSUVA® (difelikefalin) is the first FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease.

What future developments is Cara Therapeutics pursuing?

Cara is developing an oral formulation of difelikefalin and has initiated Phase 3 trials for additional pruritus treatments.

Where can I access the webcast of the Cara Therapeutics presentation?

The webcast will be available in the 'Events & Presentations' section of Cara's website.